Tonix Pharmaceuticals Inc. (NASDAQ: TNXP) showed a rise in stock followed by two recent developments in the company. The first is related to the development of a Covid-19 skin test in order to examine T cell immunity. The second is the announcement made by Tonix Pharmaceuticals on March 9th that the company is participating in upcoming March investor conferences. A clinical-stage pharmaceutical company, Tonix focuses on making, acquiring, and licensing small molecules and biologics for the treatment and prevention of human disease and to reduce suffering.
What is happening?
On latest news, the company’s CEO Seth Lederman is all set to participate in an upcoming virtual investors conferences which are as follows,
- 33th Annual Roth Conference which is happening on 16th of March, 2021.
- On 17 & 18 of March, Maxim emerging growth conference will take place.
- And lastly on 23 and 25 March, the CEO will participate in Investors Summit.
On March 8th, Tonix Pharmaceutical announced that the company has planned to develop a diagnostic skin test TNX-2100. This test will check the delayed-type hypersensitivity (DTH) happens in reaction to the virus SARS-CoV2, that causes COVID-19. The test, TNX-2100 is a composition of three different mixtures (TNX-2110, TNX-2120, and TNX-2130) of synthetic peptides which harmonize with different proteins of SARS-CoV-2.
- TNX-2110 represents multiple proteins from SARS-CoV-2.
- TNX-2120 only represents the spike proteins.
- Whereas TNX-2130, except for the spike proteins represents several others.
All three tests will take place during the same procedure through the application on three different parts of forearm, the process is similar to TB skin test. Side by side with the development of TNX-2100, Tonix Pharmaceutical I also in the process of making TNX-1800, a live replicating vaccine for COVID-19 which is designed to give rise to T-cell immunity.
Tonix Pharmaceutical has recorded positive immune response data in non-human primates during the fourth quarter of 2020. While this being achieved the company is also hoping to release data of non-human primate studies which involves challenges with SARS-CoV-2 in the first quarter of 2021.